1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

 
• By Joseph Haas

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Tumor microenvironment, OncoResponse profile
OncoResponse's technology focuses on the tumor microenvironment and turning "cold" tumors "hot" • Source: Alamy

To hear OncoResponse Inc. CEO Clifford Stocks tell it, his company is “approaching that interesting time point where pharma likes to partner” as it readies lead candidate OR2805 for efficacy studies in solid tumors. Currently in Phase I, OR2805 is derived from B-cells harvested from an “elite responder” to a commercial anti-PD-1 therapy and may offer an approach for transforming “cold” tumors into immuno-responsive or “hot” ones.

With an antibody-discovering platform technology that Theraclone Sciences, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 
• By Elizabeth Cairns

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

 
• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.